We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SEPRACOR PROVIDES UPDATE ON CLINICAL TRIALS FOR SEP-225289 AND LUNESTA PEDIATRICS.
- Abstract
The article reports on the findings of the Phase II clinical trial conducted by Marlborough, Massachusetts-based Sepracor Inc. concerning the effectiveness and safety of SEP-225289 for the treatment of major depressive disorder. Based on the results of the trial, the candidate drug did not meet the primary efficacy endpoint and its adverse event profile was inconsistent. It mentions that further examinations are needed for its dose exposure relationship.
- Subjects
MARLBOROUGH (Mass.); MASSACHUSETTS; SEPRACOR Inc.; CLINICAL trials; DRUG efficacy; MENTAL depression; THERAPEUTICS
- Publication
Psychiatry (1550-5952), 2009, Vol 6, Issue 7, p51
- ISSN
1550-5952
- Publication type
Article